Summary

Dr. Duxin Sun is the Associate Dean for Research in the College of Pharmacy at the University of Michigan. He is the Charles Walgreen Jr. Professor of Pharmacy and Professor of Pharmaceutical Sciences. Dr. Sun serves as the Director of Pharmacokinetics (PK) Core. Dr. Sun also has joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and University of Michigan’s Comprehensive Cancer Center. Dr. Sun received broad training in Pharmaceutical Sciences (PhD), Molecular Biology (visiting scientist), Pharmacology (MS) and Pharmacy (BS). 

Dr. Sun’s research interests focus on drug discovery, nanomedicine and pharmacokinetics. Dr. Sun has published more than 260 papers (H-index 66), mentored 37 PhD students and 70 postdoctoral fellows/visiting scientists. Dr. Sun is a Fellow of American Association of Pharmaceutical Scientists (AAPS) and has served as chair of the PPB (Physical Pharmacy and Biopharmaceutics) in AAPS. Dr. Sun served on FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee.  Dr. Sun has served on study sections for NIH and FDA. 


Feature Story
Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity

Never thought my lab would work on anti-viral drugs since we mainly focus on anti-cancer drug discovery, but COVID19 changed everything. Even if the pandemic ends today, there will be patients die from severe disease of COVID19. We still need anti-viral drugs to treat COVID19 with severe disease, since Gilead's Remdesivir only has limited efficacy in these patients, while Pfizer's Paxlovid only works in COVID19 patient with moderate disease but does not work in COVID19 patients with severe disease. By applying our new STAR system (structure-tissue selectivity-activity-relationship), we further optimized remdesivir for better anti-SARS-CoV-2 activity and better tissue (lung) selectivity. Hope this will help to treat COVID19 patients with severe disease. "Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity". J Med Chem, 2022, in press

Research Interests

Selected Publications